Walter Public Investments Inc. Has $9.14 Million Holdings in IQVIA Holdings Inc. $IQV

Walter Public Investments Inc. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 18.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 53,572 shares of the medical research company’s stock after selling 12,132 shares during the quarter. IQVIA comprises about 2.2% of Walter Public Investments Inc.’s investment portfolio, making the stock its 23rd largest position. Walter Public Investments Inc.’s holdings in IQVIA were worth $9,136,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Kepler Cheuvreux Suisse SA grew its holdings in IQVIA by 5.0% during the 1st quarter. Kepler Cheuvreux Suisse SA now owns 5,724 shares of the medical research company’s stock worth $976,000 after acquiring an additional 270 shares during the last quarter. Praxis Investment Management Inc. lifted its position in shares of IQVIA by 15.3% during the first quarter. Praxis Investment Management Inc. now owns 2,589 shares of the medical research company’s stock worth $442,000 after purchasing an additional 344 shares in the last quarter. V Square Quantitative Management LLC grew its stake in shares of IQVIA by 9.7% during the first quarter. V Square Quantitative Management LLC now owns 4,322 shares of the medical research company’s stock valued at $737,000 after purchasing an additional 383 shares during the last quarter. Nixon Peabody Trust Co. increased its holdings in shares of IQVIA by 20.5% in the first quarter. Nixon Peabody Trust Co. now owns 72,175 shares of the medical research company’s stock valued at $12,309,000 after purchasing an additional 12,261 shares in the last quarter. Finally, QRG Capital Management Inc. increased its holdings in shares of IQVIA by 592.6% in the first quarter. QRG Capital Management Inc. now owns 31,124 shares of the medical research company’s stock valued at $5,308,000 after purchasing an additional 26,630 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 0.3%

Shares of NYSE IQV opened at $206.38 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The firm has a market capitalization of $34.44 billion, a P/E ratio of 25.57, a P/E/G ratio of 1.78 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company’s 50 day simple moving average is $176.95 and its 200 day simple moving average is $189.30.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA declared that its board has authorized a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Evercore reaffirmed an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Robert W. Baird lifted their target price on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. Finally, Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $222.00.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.